ANIX vs. ENZ, PMD, QTTB, NBTX, URGN, VTYX, KMDA, VNDA, AVIR, and ADCT
Should you be buying Anixa Biosciences stock or one of its competitors? The main competitors of Anixa Biosciences include Enzo Biochem (ENZ), Psychemedics (PMD), Q32 Bio (QTTB), Nanobiotix (NBTX), UroGen Pharma (URGN), Ventyx Biosciences (VTYX), Kamada (KMDA), Vanda Pharmaceuticals (VNDA), Atea Pharmaceuticals (AVIR), and ADC Therapeutics (ADCT). These companies are all part of the "medical" sector.
Anixa Biosciences (NASDAQ:ANIX) and Enzo Biochem (NYSE:ENZ) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, community ranking, profitability, risk, valuation, institutional ownership and dividends.
29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 36.9% of Enzo Biochem shares are owned by institutional investors. 22.6% of Anixa Biosciences shares are owned by company insiders. Comparatively, 15.5% of Enzo Biochem shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Anixa Biosciences had 4 more articles in the media than Enzo Biochem. MarketBeat recorded 4 mentions for Anixa Biosciences and 0 mentions for Enzo Biochem. Anixa Biosciences' average media sentiment score of 1.19 beat Enzo Biochem's score of 0.55 indicating that Anixa Biosciences is being referred to more favorably in the media.
Enzo Biochem received 194 more outperform votes than Anixa Biosciences when rated by MarketBeat users. However, 64.29% of users gave Anixa Biosciences an outperform vote while only 56.53% of users gave Enzo Biochem an outperform vote.
Enzo Biochem has a net margin of 99.28% compared to Anixa Biosciences' net margin of 0.00%. Enzo Biochem's return on equity of -36.71% beat Anixa Biosciences' return on equity.
Anixa Biosciences has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, Enzo Biochem has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500.
Enzo Biochem has higher revenue and earnings than Anixa Biosciences.
Anixa Biosciences currently has a consensus target price of $12.00, indicating a potential upside of 393.83%. Given Anixa Biosciences' higher possible upside, equities analysts plainly believe Anixa Biosciences is more favorable than Enzo Biochem.
Summary
Anixa Biosciences beats Enzo Biochem on 8 of the 15 factors compared between the two stocks.
Get Anixa Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anixa Biosciences Competitors List
Related Companies and Tools
